Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol–conjugated uricase) in patients with treatment‐failure gout: Results of a phase II randomized study
Top Cited Papers
- 29 August 2008
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (9) , 2882-2891
- https://doi.org/10.1002/art.23810
Abstract
Objective To assess the efficacy of pegloticase in achieving and maintaining plasma urate levels of <6 mg/dl in gout patients in whom other treatments have failed, and to assess the pharmacokinetics and safety of pegloticase. Methods Forty‐one patients were randomized to undergo 12–14 weeks of treatment with pegloticase at 1 of 4 dosage levels: 4 mg every 2 weeks, 8 mg every 2 weeks, 8 mg every 4 weeks, or 12 mg every 4 weeks. Plasma uricase activity, plasma urate, and antipegloticase antibodies were measured, pharmacokinetic parameters were assessed, and adverse events were recorded. Results The mean plasma urate level was reduced to ≤6 mg/dl within 6 hours in all dosage groups, and this was sustained throughout the treatment period in the 8 mg and 12 mg dosage groups. The most effective dosage was 8 mg every 2 weeks. Twenty‐six patients received all protocol doses. The percentage of the patients in whom the primary efficacy end point (plasma urate <6 mg/dl for 80% of the study period) was achieved ranged from 50% to 88%. Gout flares occurred in 88% of the patients. The majority of adverse events (excluding gout flare) were unrelated to treatment and were mild or moderate in severity. Infusion‐day adverse events were the most common reason for study withdrawal (12 of 15 withdrawals). There were no anaphylactic reactions. Antipegloticase antibody, present in 31 of 41 patients, was associated with reduced circulating half‐life of pegloticase in some patients. Conclusion Pegloticase, administered in multiple doses, was effective in rapidly reducing and maintaining plasma urate levels at ≤6 mg/dl in most patients in whom conventional therapy had been unsuccessful due to lack of response, intolerability, or contraindication.Keywords
This publication has 10 references indexed in Scilit:
- Uricase and other novel agents for the management of patients with treatment-failure gout.Current Rheumatology Reports, 2007
- Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory goutArthritis & Rheumatism, 2007
- Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and GoutNew England Journal of Medicine, 2005
- Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidaseArthritis Research & Therapy, 2005
- A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapyArthritis Care & Research, 2004
- The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profilePharmacology & Therapeutics, 2004
- Efficacy and Safety of Intravenous Immunoglobulin for Immune-Mediated Skin DiseaseAmerican Journal of Clinical Dermatology, 2004
- Risks associated with the use of intravenous immunoglobulinTransfusion Medicine Reviews, 2003
- Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic goutArthritis Care & Research, 2002
- Use of 3,5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazone chromogenic system in direct enzymic assay of uric acid in serum and urine.Clinical Chemistry, 1980